This article has Open Peer Review reports available.
Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: a case report and review of the literature
© Brizzi et al. 2015
Received: 1 April 2015
Accepted: 10 November 2015
Published: 18 November 2015
Paraneoplastic neurological syndrome (PNS) is a heterogeneous group of disorders affecting any part of the nervous system, in a patient affected by cancer. PNS is estimated to occur in 0.01 to 8 % of cancer patients, with higher incidence in those with small cell lung cancer, gynecological tumours or hematological disease. Paraneoplastic cerebellar degeneration (PCD) is the most common PNS, but it has never been reported in patients with pancreatic well-differentiated neuroendocrine tumours.
A 61-year-old man presented with an unusual PNS and absence of circulating neural auto-antibodies. Subsequently, contrast-enhanced computed tomography revealed a large pancreatic mass, together with multiple liver metastases, histologically diagnosed as a well-differentiated neuroendocrine tumor. Initial treatment with long-acting somatostatin analogue (octreotide LAR) and prednisone achieved a biochemical response (reduction of chromogranin A level) and a radiological disease control, but patient experienced only a brief improvement of neurological symptoms. Seven months after the onset of the symptoms, he died from neurological impairment.
PNS can be associated with metastatic non-functioning well-differentiated pancreatic neuroendocrine tumors. These tumors may be unresponsive to treatment with somatostatin analogues and an early neurological treatment should be considered for the optimal management of these uncommon cases.
Paraneoplastic neurological syndrome (PNS) is a heterogeneous group of disorders affecting any part of the central, peripheral or autonomic nervous system, associated with the presence of a cancer. The etiology of these syndromes has not been fully elucidated yet. Several authors investigated the presence of tumour-associated antibodies against neural antigens (anti-neural antibodies), defining PNS as an immuno-mediated syndrome . However, the absence of anti-neural antibodies does not exclude a diagnosis of PNS, as well as their presence is not sufficient to confirm this diagnosis . This syndrome occurs in 0.01 to 8 % of patients with cancer, and its incidence is higher mainly associated with small cell lung cancer, gynecological tumors as well as hematological diseases . In patients with well-differentiated neuroendocrine tumours PNS has been only occasionally reported.
Paraneoplastic cerebellar degeneration (PCD) is the most common PNS and occurs as a result of autoimmune damage to the cerebellum. It is characterized by subacute cerebellar symptoms and exhibits varying clinical features: In some cases only cerebellar involvement is noted, whereas other sites of the nervous system can be involved in addition to the cerebellum. The syndrome develops within days or a few weeks with dystasia, loss of ambulation, dysarthria, saccadic gaze, pursuit, and nystagmus . Diagnosis is driven by signs and symptoms, because imaging techniques fail to show early abnormalities. Radiological signs of cerebellar atrophy have been reported only months after the clinical onset of the syndrome.
We report the case of a patient with symptoms of sub-acute cerebellar degeneration, in which a pancreatic well-differentiated neuroendocrine tumor was subsequently diagnosed.
Case report of paraneoplastic neurological syndrome associated with well-differentiated pancreatic neuroendocrine tumor
Lambert-Eaton myasthenic syndrome
Bertani et al. 
Paraneoplastic optic neuropathy
CAR, CRMP-5, anti retinal negative, anti-optic nerve positive
Slamovits et al. 
Anti Hu, Yo, Ri, Ma1-2, CV2, amphiphysin: negative, GAD positive
Hernández-Echebarría et al. 
PCD is the most common PNS representing 24 % of all the PNS, with well-defined criteria [3, 9]. In this case, the onset and the time course of the neurological syndrome fits the diagnosis of PCD, but grossly abnormal EEG and the severity of global encephalopathy leading to death is non typical for this syndrome.
To the best of our knowledge, the association between a pancreatic WDNET and the detection of a PCD has not previously been reported. Neurological impairment and not tumor progression is often the cause of death in these patients. Thus, treatment of PNS is symptomatic and the complete surgical resection of the tumor is highly encouraged .
Patients bearing well-differentiated, non-functioning pancreatic neuroendocrine cancers usually present with a slow-growing, less aggressive disease, with life expectancy of more than 24 months . Octreotide LAR is the treatment of choice. In the absence of response, or in case of progression, chemotherapy or everolimus may be considered . These treatments are associated with a disease control (clinical and/or radiological) in more than 50 % of the patients . The case here reported had an atypical - and somehow unexpected - clinical course. After three months of therapy, the patient presented with an improvement of the neurological symptoms and a good biochemical response, with a good correlation between anti-tumor activity and control of clinical symptoms, as usually observed in patients with this type of tumors. Instead, the neurological impairment rapidly progressed independently from the primary tumor response, and precluded the administration of additional treatments. No immunosuppressant agents or treatment with immunoglobulins was administered. This was due to the quick and fatal progression of the neurological symptoms. Furthermore, we recorded the absence of any immunoglobulin in the CSF, so it is questionable whether such therapies would have been beneficial in solving or at least stopping the progressive deterioration of the overall condition.
This is the first report of an advanced well-differentiated non-functioning neuroendocrine pancreatic tumor with associated an acute paraneoplastic neurological syndrome such as PCD. Neurological symptoms progressed independently from the oncological course of the disease. Thus an early neurological aggressive treatment should be considered, even in the presence of a biochemical or radiological response of the neuroendocrine tumor.
Written informed consent for the publication of the clinical details and the radiological images was obtained from the wife of the patient. A copy of the consent form is available for review by the Editor of this journal.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Leypoldt F, Wandinger K-P. Paraneoplastic neurological syndromes. Clin Exp Immunol. 2014;175:336–48.View ArticlePubMedPubMed CentralGoogle Scholar
- Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135–40.View ArticlePubMedPubMed CentralGoogle Scholar
- Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7:327–40.View ArticlePubMedPubMed CentralGoogle Scholar
- Trouillas P, Takayanagi T, Hallett M, Currier R, Subramony S, Wessel K. International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome. J Neurol Sci. 1997;145:205–11.View ArticlePubMedGoogle Scholar
- Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials. Stroke. 2007;38:1091–6.View ArticlePubMedGoogle Scholar
- Bertani H, Messerotti A, Di Benedetto F, Manta R, Greco M, Casoni F, et al. Unusual paraneoplastic syndrome accompanies neuroendocrine tumours of the pancreas. Case Rep Med. 2011;309:149.Google Scholar
- Slamovits TL, Posner JB, Reidy DL, Thirkill CE, Keltner JL. Pancreatic neuroendocrine paraneoplastic optic neuropathy: confirmation with antibody to optic nerve and hepatic metastasis. J Neuroophthalmol. 2013;33(1):21–5.View ArticlePubMedGoogle Scholar
- Hernández-Echebarría L, Saiz A, Arés A, Tejada J, García-Tuñón L, Nieves C, et al. Paraneoplastic encephalomyelitis associated with pancreatic tumor and anti-GAD antibodies. Neurology. 2006;66(3):450–1.View ArticlePubMedGoogle Scholar
- Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010;67(3):330–5.View ArticlePubMedGoogle Scholar
- Braik T, Evans AT, Telfer M, McDunn S. Paraneoplastic neurological syndromes: unusual presentations of cancer. A practical review. Am J Med Sci. 2010;340(4):301–8.View ArticlePubMedGoogle Scholar
- Giustina A, Mazziotti G, Maffezzoni F, Amoroso V, Berruti A. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. Expert Opin Investig Drugs. 2014;23(12):1619–35.View ArticlePubMedGoogle Scholar
- Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist. 2014;19(9):966–74.View ArticlePubMedPubMed CentralGoogle Scholar